$34.06 -$0.67 (-1.9%)

04:30 PM EDT on 04/24/19

Puma Biotechnology Inc. (NASDAQ:PBYI)

CAPS Rating: 3 out of 5

Current Price $34.06 Mkt Cap $1.3B
Open $34.50 P/E Ratio 0.00
Prev. Close $34.73 Div. (Yield) $0.00 (0.0%)
Daily Range $33.85 - $35.22 Volume 188,814
52-Wk Range $19.86 - $43.90 Avg. Daily Vol. 22

Caps

How do you think NASDAQ:PBYI will perform against the market?

Add Stock to CAPS Watchlist

All Players

46 Outperform
19 Underperform
 

All-Star Players

14 Outperform
9 Underperform
 

Wall Street

2 Outperform
1 Underperform
 

Top NASDAQ:PBYI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

lookbeforeuleap (91.01)
Submitted November 15, 2014

a 10 bagger from 3/13/2013

YourDailyBear (53.08)
Submitted January 14, 2016

Puma has 0 Revenue and a $1.57 Billion market cap. Crazy overvalued and bearish trend.

NASDAQ:PBYI VS S&P 500 (SPY)

Fools bullish on NASDAQ:PBYI are also bullish on:

Fools bearish on NASDAQ:PBYI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about PBYI.

Recs

0
Member Avatar TMFBlacknGold (90.23) Submitted: 1/22/2019 11:38:45 AM : Outperform Start Price: $24.92 NASDAQ:PBYI Score: +26.83

From 01/22/2019:

"Evaluating Puma Biotechnology isn't quite straightforward. On one hand, it owns only one asset that appears to be growing slower than analysts predicted. On the other hand, that one asset has proven to be a successful treatment in multiple clinical trials and looks poised to deliver the business to profitable operations. While upcoming market launches should boost sales growth in 2019, investors will need to ensure the added marketing expenses don't unravel the progress made in reducing overhead last year.

Nonetheless, given the low valuation and the overnight reduction in operating expenses recently, I think investors can comfortably begin a position in Puma Biotechnology at a market cap of around $950 million. Just know that it exited 2018 with a market cap of only $775 million -- so Wall Street clearly has no problems going lower. I think a price-to-sales ratio of 4.7 hints that Wall Street got carried away in doling out punishment last year."

https://www.fool.com/investing/2019/01/22/is-puma-biotechnology-a-buy.aspx

Recs

0
Member Avatar TerryHogan (99.97) Submitted: 10/23/2018 1:58:57 AM : Underperform Start Price: $39.84 NASDAQ:PBYI Score: +22.38

I know nothing about their products (I don't think it's athletic wear, but I can't say for sure) or drug pipelines, or approvals, or anything. I just know they increased sales 10X and still didn't have positive earnings. Last quarter revenue was down, and they'll still need to double earnings to make a profit. Most buyers of this are hoping for a buyout I think. That's a risk to shorting this, but I don't think profits are a threat any time soon.

Recs

0
Member Avatar TMFEBCapital (86.21) Submitted: 7/6/2018 3:45:30 PM : Outperform Start Price: $59.65 NASDAQ:PBYI Score: -49.19

I'm not going to bet against Auerbach. The successful lobbying for CHMP re-review is the latest example of his being able overcome naysayers. Given Nerlynx potential to win greater use and his past M&A exit with Cougar/JNJ, I'm thinking this one makes sense to buy here.

Leaderboard

Find the members with the highest scoring picks in PBYI.

Score Leader

MajorBob04

MajorBob04 (99.54) Score: +219.52

The Score Leader is the player with the highest score across all their picks in PBYI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
sobek1 62.01 8/6/2014 Underperform 1Y $230.97 -85.25% +52.94% +138.19 0 Comment
jayningpan 83.99 8/18/2014 Underperform 5Y $262.01 -87.00% +48.22% +135.22 0 Comment
CramersSkeeDaddy 94.95 7/23/2014 8/7/2015 Underperform 3Y $232.11 -85.33% +47.10% +132.43 1 Comment
bumpyjr 66.76 7/23/2014 Underperform 5Y $230.35 -85.21% +47.11% +132.32 0 Comment
newbie07 39.87 7/24/2014 Underperform 5Y $226.00 -84.93% +47.00% +131.93 0 Comment
theMetz 33.29 7/24/2014 Underperform 1Y $226.00 -84.93% +47.00% +131.93 0 Comment
jackbot 95.62 7/24/2014 Underperform 5Y $214.06 -84.09% +47.10% +131.19 0 Comment
Halffrenzy 25.81 2/28/2014 Underperform 5Y $124.55 -72.65% +56.39% +129.04 0 Comment
kevrose31 77.88 1/10/2014 Underperform 1Y $110.14 -69.08% +58.89% +127.97 0 Comment
doug9694 83.14 3/11/2015 Underperform 5Y $235.66 -85.55% +42.42% +127.96 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 86.01 7/10/2015 Underperform 3W $106.25 -67.94% +40.87% +108.81 0 Comment
TrackCitigroup 89.18 4/21/2014 Outperform NS $74.73 -54.42% +56.77% -111.19 0 Comment
TrackUBS 91.30 12/19/2013 Outperform NS $98.76 -65.51% +61.31% -126.82 0 Comment

Advertisement